{
    "url_original": "https://www.wsj.com/articles/jazz-pharmaceuticals-to-buy-cannabis-based-drugmaker-gw-pharma-for-6-7-billion-11612370417?mod=markets_lead_pos7",
    "url": "jazz-pharmaceuticals-to-buy-cannabis-based-drugmaker-gw-pharma-for-6-7-billion-11612370417",
    "title": "Jazz Pharmaceuticals to Buy Cannabis-Based Drugmaker GW Pharma for $6.7 Billion",
    "sub_head": "Jazz bets drugs derived from the marijuana plant will be big players in treating neuroscience conditions",
    "category_1": "Business",
    "image_1_url": "https://images.wsj.net/im-294270?width=620&size=1.5",
    "image_1": "im-294270.jpg",
    "time": "2021-02-03 11:40:00",
    "body": "Jazz Pharmaceuticals  PLC has agreed to acquire  GW Pharmaceuticals  PLC, maker of the first epilepsy drug derived from the marijuana plant, for $6.7 billion in cash and stock.<br />The deal, combining two neuroscience drugmakers, marks a bet by Jazz on the long-term prospects for cannabis-based therapies.<br />GW Pharmaceuticals’ drug Epidiolex is used to treat rare forms of epilepsy and had global sales of $510 million last year, the companies said Wednesday. U.K.-based GW launched the drug in 2018 at a price of about $32,500 per patient annually in the U.S.<br />The deal will strengthen Jazz’s neuroscience drug pipeline and add a potential blockbuster product in Epidiolex, which has the near-term potential to reach $1 billion in global annual sales, Jazz Chief Executive Bruce Cozadd said in an interview.<br />GW’s pipeline includes cannabinoid-based drugs being tested as treatments for autism, schizophrenia and other conditions."
}